Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 551 - 600 out of 22,983

Document Document Title
WO/2023/056556A1
Here is disclosed isolated or purified monoclonal antibodies, or an antigen-binding fragments thereof, which binds to human CD3, and which comprises: a CDRH1 amino acid sequence of SEQ ID NO: 150, a CDRH2 amino acid sequence of SEQ ID NO...  
WO/2023/056969A1
Provided are novel bispecific antibodies, comprising at least one binding domain capable of specifically binding to CD47 and at least one binding domain capable of specifically binding to CD20. Also provided are methods of producing thes...  
WO/2023/056530A1
The disclosure generally relates to a method of bioconjugation where two or more biomolecules are conjugated via metal coordination complexes. More particularly, the disclosure generally relates to the use of certain metal coordination c...  
WO/2023/056970A1
Provided are novel bispecific antibodies, comprising at least one binding domain capable of specifically binding to CD47 and at least one binding domain capable of specifically binding to HER2. Further provided are methods of producing t...  
WO/2023/051412A1
A β-NGF fusion protein, and a preparation method therefor and the use thereof. Specifically, the present invention relates to a β-NGF fusion protein, which contains: (a) a light chain containing β-NGF; and (b) a heavy chain containing...  
WO/2023/054714A1
The present invention provides: a conjugate of a functional substance and an antibody, in which the binding ratio between the antibody and the functional substance is controlled to within a specific range, said conjugate being exceptiona...  
WO/2023/051611A1
A SARS-CoV-2-specific polypeptide and an application thereof. 271 15-18 polymer SARS-CoV-2 peptide fragments formed by overlapping 10 amino acids are designed, the amino acid sequences are as shown in SEQ ID NO. 1-SEQ ID NO. 271, and the...  
WO/2023/054706A1
The present invention provides a conjugate of an antibody and a functional substance, said conjugate having excellent desired properties, or a salt thereof. More particularly, the present invention provides a conjugate of an antibody and...  
WO/2023/051480A1
Provide compositions of a sialylated core peptide (071 core) and compositions of proteins based on fusion of one copy or more copies of the peptide to the Fc fragment of human immunoglobulin and their use in treating diseases propagated ...  
WO/2023/050644A1
The present invention relates to a chimeric allosteric transcription factor for regulating genes of interest in mammalian cells and a regulatory element group comprising the chimeric allosteric transcription factor, and an inducible expr...  
WO/2023/050031A1
The present invention belongs to the technical field of characterization of the properties of target analytes, and specifically provides a mutant of a porin monomer, a protein pore containing same, and the use thereof in the detection of...  
WO/2023/056373A1
The current application fulfills a need for methods of making bi-specific CAR T-cells that have high efficacy. Aspects of the disclosure relate to a method for manufacturing a CD19/CD20 bi-specific chimeric antigen receptor (CAR) T cell ...  
WO/2023/050826A1
Provided herein are immunoconjugate molecules containing a TNF-α polypeptide and a masking moiety capable of inhibiting and activating the TNF-α activity under suitable conditions. Also provided herein are methods for producing the imm...  
WO/2023/051798A1
An anti-lL23 antibody fusion protein and uses thereof, the anti-lL23 antibody fusion protein containing anti IL23 antibodies and TAC polypeptides, and the IL23 antibodies specifically binding the human IL23 p19 subunit. The anti-lL23 ant...  
WO/2023/050661A1
A pheromonicin against SARS-CoV-2. Antibody mimetics, i.e. two 28 peptides, are designed for the first time by means of selecting the E protein and M protein of SARS-CoV-2, which are conservative and have a low mutation probability, as t...  
WO/2023/051414A1
Provided are a MSLN-targeting antibody, and a multi-specific antibody, chimeric antigen receptor, antibody conjugate, pharmaceutical composition and kit comprising same, and a use of these in diagnosis/treatment/prevention of diseases as...  
WO/2023/050006A1
This disclosure generally relates to modified interleukin-12 (IL12) or IL23 p40 polypeptides with alterations to reduce binding affinity to its receptor subunit in order to create an IL12 or IL23 protein that is less toxic as compared to...  
WO/2023/051701A1
An mRNA against SARS-CoV-2 infection. The template DNA of the mRNA comprises an antigen encoding region. The antigen encoding region encodes a signal peptide-free S protein of a SARS-CoV-2 Delta mutant, wherein the S protein of the Delta...  
WO/2023/051462A1
The present invention relates to a fusion polypeptide of GLP-1 analog. Specifically, the present invention relates to a fusion polypeptide of GLP-1 analog or a pharmaceutically acceptable salt thereof, wherein the fusion polypeptide of G...  
WO/2023/051850A1
Disclosed are a recombinant fusion protein derived from an HR region of an S2 protein of SARS-CoV-2 and an application of the recombinant fusion protein. The SARS-CoV-2 recombinant fusion protein is a recombinant fusion protein obtained ...  
WO/2023/051660A1
Provided are a drug for treating Sjogren's syndrome using a TACI-Fc fusion protein, and a dosage regimen, a dosing interval and an administration mode thereof. The results show that the provided TACI-Fc fusion protein significantly impro...  
WO/2023/044774A1
Provided are recombinant peptides comprising a recombinant human p75 TNF receptor and TPO mimetic peptides linked by an Fc fragment of IgG1. The recombinant peptides can form a homodimer by inter-chain disulfide bond in the Fc region and...  
WO/2023/046110A1
Provided is an engineered immune cell co-expressing CCR2b, wherein the engineered immune cell is a T cell or an NK cell. NKG2D extracellular domain-containing CAR molecules and CCR2b are co-expressed in a CAR-T cell, so that the sensitiv...  
WO/2023/048290A1
This method for producing a polypeptide comprising expressing a polypeptide as a tag-added polypeptide comprises expressing the tag-added polypeptide from a nucleic acid having: a base sequence which is arranged immediately after a start...  
WO/2023/049926A2
Provided herein are fusion polypeptides comprising a Cpfl domain lacking nuclease activity and an endonuclease domain. Also provided herein are fusion polypeptides further comprising a genomic modification domain, which in some embodimen...  
WO/2023/045470A1
The present invention provides a recombinant thyroid stimulating hormone receptor protein, a preparation method therefor and an application thereof. The recombinant thyroid stimulating hormone receptor protein comprises a TSHR protein ex...  
WO/2023/049774A1
Described herein is a generalizable strategy to rapidly and irreversibly activate protein function with full spatiotemporal control. Through development of an exogenously triggerable self-assembling protein construct, bioactive proteins ...  
WO/2023/044991A1
Provided is a chimeric antigen receptor specifically targeting a tumor EpCAM antigen, comprising an extracellular antigen recognition domain, a transmembrane domain and an intracellular signaling domain, the extracellular antigen recogni...  
WO/2023/046116A1
The present invention relates to the field of biomedicine, and in particular to a polypeptide complex of interleukin 15 and a receptor thereof, and a use thereof. A non-natural interchain bond is present between IL15 and IL15Rα in the p...  
WO/2023/046047A1
Provided are a heterodimeric protein and an application thereof. The heterodimeric protein contains: (1) a light chain and a heavy chain 1, which are compounded to form a target part expressing binding specificity for a tumor antigen or ...  
WO/2023/047129A1
The invention relates to fusion polypeptides, and to immunogenic polypeptides and their use as vaccines for treating, preventing or ameliorating a wide range of infectious diseases, for example caused by a virus, bacterium or fungus, or ...  
WO/2023/045997A1
Provided are an anti-Claudin18.2 antibody or an antigen binding fragment thereof and a use thereof. Further provided are a bispecific antibody, a multispecific antibody, a multi-functional fusion protein and a composition thereof contain...  
WO/2023/046156A1
Provided are IL-2 variants and polypeptide complexes comprising the IL-2 variants, the methods of producing the same and the uses thereof. The IL-2 variants and fusion proteins can be used as a potent agent for the treatment of cancers, ...  
WO/2023/048151A1
The present invention provides a compound having a corona virus proliferation inhibition activity, and/or a pharmaceutical composition containing the compound having a corona virus proliferation inhibition activity. A compound represente...  
WO/2023/045361A1
Provided are a fusion protein of an anti-TIGIT antibody and IL2 or a variant thereof, and an application thereof. Specifically, a fusion protein is provided, which comprises: (a) a first polypeptide comprising an anti-TIGIT antibody or a...  
WO/2023/045001A1
A modified SIS membrane for tissue repair, a preparation method therefor and a use thereof. Specifically provided is a composition comprising a fusion polypeptide-modified SIS film and an extracellular vesicle, as well as a preparation m...  
WO/2023/044457A1
The present disclosure generally relates to, inter alia, a class of chimeric switch receptors containing an endodomain of an IL-9 receptor, engineered to modulate transcriptional regulation in a ligand-dependent manner. The disclosure al...  
WO/2023/040667A1
Provided is a recombinant fusion protein, comprising a PD-L1 antibody or antibody fragment thereof. At least one paratope of the PD-L1 antibody or antibody fragment thereof is connected to an extracellular Ig-like domain of a signal regu...  
WO/2023/044318A2
The present invention is related to, inter alia, de novo IL-2Rβ binding polypeptides.  
WO/2023/044348A1
The present invention provides methods of treating pulmonary disorders with modulators of the Wnt signaling pathway. Also provided are methods of related methods of dosing and pharmaceutical compositions.  
WO/2023/044290A1
Disclosed herein are small molecule GIP/GLP-1 dual receptor agonist compositions, pharmaceutical compositions, the use and preparation thereof.  
WO/2023/044461A2
The present disclosure generally relates to, inter alia, a class of chimeric switch receptors containing an endodomain of an IL-9 receptor, engineered to modulate transcriptional regulation in a ligand-dependent manner. The disclosure al...  
WO/2023/040963A1
The present disclosure provides a novel polypeptide. Also provided is an ophthalmic composition for treating or preventing dry eye (DE) or DE associated disorders. Also provided is a method for treating or preventing DE or DE associated ...  
WO/2023/044321A1
The present invention discloses proteolytically cleavable peptide (CP) substrates, polypeptides, polypeptide constructs and prodrug constructs comprising the proteolytically cleavable peptides (e.g., cytokine prodrugs), and methods of us...  
WO/2023/039667A1
The present disclosure describes multivalent (e.g., decavalent or dodecavalent) polypeptide constructs capable of binding to one or more viral spike protein(s) and capable of intercepting the interaction of a spike protein of a viral par...  
WO/2023/040205A1
Provided are a fusion protein and a protein combination thereof, the fusion protein comprising nicotinamide riboside kinase (NRK) and ATP cyclase linked to each other using a linker, and the protein combination comprising the NRK and the...  
WO/2023/043473A1
A therapeutic composition is described that can be used for treating or prevention of diseases association with modulation of activity of human TGF-β. In certain aspects, the disclosed invention is based, on engineering of a heterodimer...  
WO/2023/036191A1
A vaccine for a novel coronavirus SARS-CoV-2 Delta variant and an application, the vaccine comprising a fusion protein, and the fusion protein comprising: (1) an interferon or a functional fragment thereof; (2) a novel coronavirus SARS-C...  
WO/2023/036043A1
Provided are an anti-cancer binding molecule and the use thereof, and specifically provided is a bispecific binding molecule of 4-1BB and GPC3. The bispecific binding molecule comprises a first domain that specifically binds to 4-1BB, an...  
WO/2023/036270A1
Disclosed is an antigen-targeting, anti-CD16A and immune effector cell-activating trifunctional fusion protein, which comprises a CD16A binding region that specifically binds to CD16A, a TAA binding region that specifically binds to a tu...  

Matches 551 - 600 out of 22,983